Program
XT-150
A development code.
Its studies are mostly in Osteoarthritis, Knee · Amyotrophic Lateral Sclerosis · Back Pain · Neuralgia · Osteoarthritis, led by Xalud Therapeutics.
Furthest: phase 2, since Oct 9, 20198 company-led studies, 1 open or runningNext primary completion: Jun 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Xalud Therapeutics | 81 open or running | phase 2since Oct 9, 2019 | Sep 11, 2017 | Jun 2028phase 1 · NCT06704347 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 11, 2017First study: phase 1 study in Osteoarthritis, KneeFirst studyNCT03282149 · 24 enrolled · Australia
- Mar 13, 2018Phase 1 study in Osteoarthritis, KneeNCT03477487 · 32 enrolled · United States
- Dec 6, 2018Phase 1 study in Osteoarthritis, KneeNCT03769662 · 16 enrolled · Australia
- Oct 9, 2019Phase 2 study in Osteoarthritis, KneeNCT04124042 · 289 enrolled · United States, Australia
- Jun 24, 2020Phase 1 study in NeuralgiaNCT04466410 · 5 enrolled · Australia
- Apr 7, 2021Phase 2 study in Osteoarthritis, SpineNCT04841512 · Australia
- Dec 13, 2021Phase 2 study in Back PainNCT05196919 · 75 enrolled · United States
- Nov 20, 2024Phase 1 study in Amyotrophic Lateral SclerosisNCT06704347 · 8 planned · United States
Ahead
- Jun 2028Primary completion: phase 1 study in Amyotrophic Lateral SclerosisNCT06704347
TargetBeta
IL10 →read by rule
“XT-150 is a small piece of plasmid DNA (genetic material) that produces a variant of the anti-inflammatory cytokine, Interleukin 10 (IL-10).”study text, by rule · the study
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06704347Amyotrophic Lateral Sclerosis · United States | 1 | Not yet recruiting | Jun 2028 | 8 |
| NCT05196919Back Pain · United States | 2 | Completed | Sep 20, 2023 | 75 |
| NCT04841512Osteoarthritis, Spine · Australia | 2 | Withdrawn | Mar 1, 2022 | 0 |
| NCT04466410Neuralgia · Australia | 1 | Terminated | Sep 27, 2022 | 5 |
| NCT04124042Osteoarthritis, Knee · United States, Australia | 2 | Completed | Apr 26, 2022 | 289 |
| NCT03769662Osteoarthritis, Knee · Australia | 1 | Completed | Oct 30, 2019 | 16 |
| NCT03477487Osteoarthritis, Knee · United States | 1 | Completed | Jul 19, 2019 | 32 |
| NCT03282149Osteoarthritis, Knee · Australia | 1 | Completed | Mar 31, 2019 | 24 |
How it is read
Names in the registry
- “XT-150”, 8 entries
Codes read as this program: XT150.
Conditions, from the studies’ own filings
- Osteoarthritis, Knee, 4 studies
- Amyotrophic Lateral Sclerosis, 1 study
- Back Pain, 1 study
- Neuralgia, 1 study
- Osteoarthritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.